论文部分内容阅读
目的:观察缬沙坦对轻、中度原发性高血压患者高敏C反应蛋白和尿微量白蛋白的影响。方法:原发性高血压患者68例为治疗组,均给予缬沙坦80 mg/次,1次/d,口服,疗程4周,检测治疗前、后血压、心率、高敏C反应蛋白和尿微量白蛋白水平,并与同期健康体检者40例(对照组)高敏C反应蛋白和尿微量白蛋白水平进行比较。结果:治疗组治疗后收缩压、舒张压,高敏C反应蛋白,尿微量白蛋白水平均较治疗前下降(P<0.05);治疗前、后心率比较差异无统计学意义(P>0.05)。治疗组治疗前、后高敏C反应蛋白,尿微量白蛋白水平均高于对照组(P<0.05)。结论:缬沙坦可降低轻、中度原发性高血压患者高敏C反应蛋白和尿微量白蛋白水平,保护肾脏功能。
Objective: To observe the effect of valsartan on high sensitivity C-reactive protein and urinary albumin in patients with mild to moderate essential hypertension. Methods: Sixty-eight patients with essential hypertension were treated with valsartan 80 mg once daily for 4 weeks. Blood pressure, heart rate, high-sensitivity C-reactive protein and urine were measured before and after treatment Microalbuminuria, and compared with the high-sensitivity C-reactive protein and urine microalbuminuria in 40 healthy people (control group) during the same period. Results: After treatment, systolic blood pressure, diastolic blood pressure, high-sensitivity C-reactive protein, and urine microalbuminuria in treatment group were significantly lower than those before treatment (P <0.05). There was no significant difference in heart rate between the two groups before treatment (P> 0.05). The levels of high sensitivity C-reactive protein and urine microalbumin in the treatment group before and after treatment were higher than those in the control group (P <0.05). Conclusion: Valsartan can reduce the levels of high sensitivity C-reactive protein and urinary albumin in patients with mild to moderate essential hypertension and protect renal function.